Question 1

Patients with vWD have a vWF activity of __________.

Accepted Answer

A)  25-100% 
B)  <30% 
C)  50-100% 
D)  5-90% 
E)  None of the above 
A)  25-100% 
B)  <30% 
C)  50-100% 
D)  5-90% 
E)  None of the above

Question 2

What is the range of pH for samples used for platelet aggregation studies?

Accepted Answer

A)  7.0-8.0 
B)  6.5-8.5 
C)  4.0-6.0 
D)  7.0-9.0 
E)  None of the above 
A)  7.0-8.0 
B)  6.5-8.5 
C)  4.0-6.0 
D)  7.0-9.0 
E)  None of the above

Question 3

__________ is defined as the time taken for a standardized skin wound to stop bleeding.

Accepted Answer

A)  Clot retraction 
B)  Bleeding time 
C)  Reptilase time 
D)  All of the above 
E)  None of the above 
A)  Clot retraction 
B)  Bleeding time 
C)  Reptilase time 
D)  All of the above 
E)  None of the above

Question 4

Fibrinogen can be quantitatively measured by a modification of the __________ because the latter clotting time of dilute plasma is inversely proportional to the concentration of fibrinogen.

Accepted Answer

A)  PT 
B)  APTT 
C)  TT 
D)  Reptilase time 
E)  None of the above 
A)  PT 
B)  APTT 
C)  TT 
D)  Reptilase time 
E)  None of the above

Question 5

Measurement of FDPs provides an indirect assay of __________.

Accepted Answer

A)  Coagulation 
B)  Fibrinolysis 
C)  Platelet adhesion 
D)  Platelet aggregation 
E)  None of the above 
A)  Coagulation 
B)  Fibrinolysis 
C)  Platelet adhesion 
D)  Platelet aggregation 
E)  None of the above

Question 6

If a patient's PT is normal and their APTT is prolonged, and corrects with a 1:1 mix with normal plasma, this could be due to:

Accepted Answer

A)  Factor V deficiency 
B)  Factor II deficiency 
C)  Factor IX deficiency 
D)  Factor VII deficiency 
E)  All of the above 
A)  Factor V deficiency 
B)  Factor II deficiency 
C)  Factor IX deficiency 
D)  Factor VII deficiency 
E)  All of the above

Question 7

A weak circulating anticoagulant that prolongs the APTT after incubation at 37°C for 1 hour is typical of:

Accepted Answer

A)  Factor VII inhibitor 
B)  Factor VIII inhibitor 
C)  Factor X inhibitor 
D)  All of the above 
E)  None of the above 
A)  Factor VII inhibitor 
B)  Factor VIII inhibitor 
C)  Factor X inhibitor 
D)  All of the above 
E)  None of the above

Question 8

Patients with a homozygous deficiency of factor XIII show dissolution of a fibrin clot within __________ hour(s).

Accepted Answer

A)  1 
B)  2 
C)  5 
D)  3 
E)  4 
A)  1 
B)  2 
C)  5 
D)  3 
E)  4

Question 9

In the enzyme-linked immunosorbent assay (ELISA) measurement of factor VIII-related antigen, the intensity of the color produced is __________ proportional to the amount of antigen present.

Accepted Answer

A)  Indirectly 
B)  Directly 
C)  Inversely 
D)  All of the above 
E)  None of the above 
A)  Indirectly 
B)  Directly 
C)  Inversely 
D)  All of the above 
E)  None of the above

Question 10

To diagnose a cause, which steps should be taken if, when performing a thrombin time, the patient's average clotting time significantly exceeds the reference range?

Accepted Answer

A)  Result the first clotting time 
B)  Run the test using a 1:1 mixture of patient's plasma and normal plasma 
C)  Run the test using a 1:5 mixture of patient's plasma and normal plasma 
D)  All of the above 
E)  None of the above 
A)  Result the first clotting time 
B)  Run the test using a 1:1 mixture of patient's plasma and normal plasma 
C)  Run the test using a 1:5 mixture of patient's plasma and normal plasma 
D)  All of the above 
E)  None of the above

Question 11

For coagulation procedures, the ratio of blood to anticoagulant is __________.

Accepted Answer

A)  5:1 
B)  10:1 
C)  9:1 
D)  1:9 
E)  None of the above 
A)  5:1 
B)  10:1 
C)  9:1 
D)  1:9 
E)  None of the above

Question 12

What is the anticoagulant of choice in most coagulation procedures?

Accepted Answer

A)  Sodium heparin 
B)  Sodium citrate, 3.2% 
C)  Sodium ethylenediaminetetraacetic acid (EDT
A)  
D)  Sodium fluoride 
E)  None of the above 
A)  Sodium heparin 
B)  Sodium citrate, 3.2% 
C)  Sodium ethylenediaminetetraacetic acid (EDT
A)  
D)  Sodium fluoride 
E)  None of the above

Question 13

Which assay of antithrombin (AT-III) involves measurement of the diameter of the precipitate circles from plasma diffused into antibody-containing agarose gel to determine the percent of antithrombin?

Accepted Answer

A)  Chromogenic substrate assay 
B)  Laurell-rocket electroimmunoassay 
C)  Radial immunodiffusion 
D)  Clotting time based on thrombin neutralization 
E)  None of the above 
A)  Chromogenic substrate assay 
B)  Laurell-rocket electroimmunoassay 
C)  Radial immunodiffusion 
D)  Clotting time based on thrombin neutralization 
E)  None of the above

Question 14

If a patient's APTT is prolonged, and their PT is normal, this could be due to all of these conditions except:

Accepted Answer

A)  Vitamin K deficiency 
B)  Hemophilia A 
C)  Lupus anticoagulant 
D)  Factor XI deficiency 
E)  Heparin 
A)  Vitamin K deficiency 
B)  Hemophilia A 
C)  Lupus anticoagulant 
D)  Factor XI deficiency 
E)  Heparin

Question 15

Which is the anticoagulant of choice for samples to be tested in the PT test?

Accepted Answer

A)  Sodium heparin 
B)  Sodium citrate, 3.2% 
C)  EDTA 
D)  Acid citrate dextrose (AC
D)  
E)  None of the above 
A)  Sodium heparin 
B)  Sodium citrate, 3.2% 
C)  EDTA 
D)  Acid citrate dextrose (AC
D)  
E)  None of the above

Question 16

In the von Willebrand's factor (vWF) ristocetin cofactor assay, washed or lyophilized and reconstituted platelets are mixed with dilutions of plasma. Ristocetin is added and the rate of __________ is proportional to von Willebrand activity.

Accepted Answer

A)  Adhesion 
B)  Aggregation 
C)  Clot lysis 
D)  All of the above 
E)  None of the above 
A)  Adhesion 
B)  Aggregation 
C)  Clot lysis 
D)  All of the above 
E)  None of the above

Question 17

The __________ is useful as a screening test for lupus anticoagulants.

Accepted Answer

A)  APTT 
B)  PT 
C)  TT 
D)  Fibrinogen degradation product (FDP) 
E)  None of the above 
A)  APTT 
B)  PT 
C)  TT 
D)  Fibrinogen degradation product (FDP) 
E)  None of the above

Question 18

The __________ is the time required for thrombin to convert fibrinogen to an insoluble fibrin clot.

Accepted Answer

A)  PT 
B)  APTT 
C)  TT 
D)  Reptilase time 
E)  None of the above 
A)  PT 
B)  APTT 
C)  TT 
D)  Reptilase time 
E)  None of the above

Question 19

The Clauss fibrinogen assay involves clotting dilutions of both patient's test plasma and calibration plasma with an excess of __________.

Accepted Answer

A)  Thrombin 
B)  Plasmin 
C)  Fibrin 
D)  t-PA 
E)  None of the above 
A)  Thrombin 
B)  Plasmin 
C)  Fibrin 
D)  t-PA 
E)  None of the above

Question 20

The normal adult value for fibrinogen is approximately __________.

Accepted Answer

A)  50-800 mg/dL 
B)  200-400 mg/dL 
C)  150-300 mg/dL 
D)  100-500 mg/dL 
E)  None of the above 
A)  50-800 mg/dL 
B)  200-400 mg/dL 
C)  150-300 mg/dL 
D)  100-500 mg/dL 
E)  None of the above

Exam 33: Coagulation Procedures

Patients with vWD have a vWF activity of __________.

What is the range of pH for samples used for platelet aggregation studies?

__________ is defined as the time taken for a standardized skin wound to stop bleeding.

Fibrinogen can be quantitatively measured by a modification of the __________ because the latter clotting time of dilute plasma is inversely proportional to the concentration of fibrinogen.

Measurement of FDPs provides an indirect assay of __________.

If a patient's PT is normal and their APTT is prolonged, and corrects with a 1:1 mix with normal plasma, this could be due to:

A weak circulating anticoagulant that prolongs the APTT after incubation at 37°C for 1 hour is typical of:

Patients with a homozygous deficiency of factor XIII show dissolution of a fibrin clot within __________ hour(s).

In the enzyme-linked immunosorbent assay (ELISA) measurement of factor VIII-related antigen, the intensity of the color produced is __________ proportional to the amount of antigen present.

To diagnose a cause, which steps should be taken if, when performing a thrombin time, the patient's average clotting time significantly exceeds the reference range?

For coagulation procedures, the ratio of blood to anticoagulant is __________.

What is the anticoagulant of choice in most coagulation procedures?

Which assay of antithrombin (AT-III) involves measurement of the diameter of the precipitate circles from plasma diffused into antibody-containing agarose gel to determine the percent of antithrombin?

If a patient's APTT is prolonged, and their PT is normal, this could be due to all of these conditions except:

Which is the anticoagulant of choice for samples to be tested in the PT test?

In the von Willebrand's factor (vWF) ristocetin cofactor assay, washed or lyophilized and reconstituted platelets are mixed with dilutions of plasma. Ristocetin is added and the rate of __________ is proportional to von Willebrand activity.

The __________ is useful as a screening test for lupus anticoagulants.

The __________ is the time required for thrombin to convert fibrinogen to an insoluble fibrin clot.

The Clauss fibrinogen assay involves clotting dilutions of both patient's test plasma and calibration plasma with an excess of __________.

The normal adult value for fibrinogen is approximately __________.

Morphology of Human Blood and Marrow Cells: Hematopoiesis

Bone Marrow

The Red Blood Cell: Structure and Function

Anemia: Diagnosis and Clinical Considerations

Evaluation of Red Blood Cell Morphology and Introduction to Platelet and White Blood Cell Morphology

Iron Metabolism and Hypochromic Anemias

Megaloblastic Anemias

Aplastic Anemia Including Pure Red Cell Aplasia and Congenital Dyserythropoietic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Introduction to Hemolytic Anemias: Intracorpuscular Defects: I Hereditary Defects of the Red Cell Membrane

Hemolytic Anemias: Intracorpuscular Defects: II Hereditary Enzyme Deficiencies

Hemolytic Anemias: Intracorpuscular Defects: III the Hemoglobinopathies

Hemolytic Anemias: Intracorpuscular Defects: Iv Thalassemia

Hemolytic Anemias: Extracorpuscular Defects

Hypoproliferative Anemia: Anemia Associated With Systemic Diseases

Cell Biology, Disorders of Neutrophils, Infectious Mononucleosis, and Reactive Lymphocytosis

Introduction to Leukemia and the Acute Leukemias

Chronic Myeloproliferative Disorders I: Chronic Myelogenous Leukemia

Chronic Myeloproliferative Disorders Ii: Polycythemia Vera, Essential Thrombocythemia, and Idiopathic Myelofibrosis

Myelodysplastic Syndromes

Chronic Lymphocytic Leukemia and Related Lymphoproliferative Disorders

The Lymphomas

Multiple Myeloma and Related Plasma Cell Disorders

Lipid Lysosomal Storage Diseases and Histiocytosis

Introduction to Hemostasis

Disorders of Primary Hemostasis: Quantitative and Qualitative Platelet Disorders and Vascular Disorders

Disorders of Plasma Clotting Factors

Interaction of the Fibrinolytic, Coagulation, and Kinin Systems; Disseminated Intravascular Coagulation; and Related Pathology

Introduction to Thrombosis and Anticoagulant Therapy

Quality Control in the Hematology Laboratory

Body Fluid Examination: the Qualitative, Quantitative, and Morphologic Analysis of Serous, Cerebrospinal, and Synovial Fluids

Hematology Methods

Principles of Automated Differential Analysis

Applications of Flow Cytometry to Hematology and Hemostasis

Molecular Diagnostic Techniques in Hematopathology

Special Stainscytochemistry

Filters